These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1752740)

  • 1. Aminoglycoside induced ototoxicity in patients with cystic fibrosis.
    Mulherin D; Fahy J; Grant W; Keogan M; Kavanagh B; FitzGerald M
    Ir J Med Sci; 1991 Jun; 160(6):173-5. PubMed ID: 1752740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive Hearing Loss among Patients with Cystic Fibrosis and Parenteral Aminoglycoside Treatment.
    Zettner EM; Gleser MA
    Otolaryngol Head Neck Surg; 2018 Nov; 159(5):887-894. PubMed ID: 29914288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of routine hearing screening in children with cystic fibrosis on aminoglycosides: A systematic review.
    Farzal Z; Kou YF; St John R; Shah GB; Mitchell RB
    Laryngoscope; 2016 Jan; 126(1):228-35. PubMed ID: 26152803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis.
    Al-Malky G; Dawson SJ; Sirimanna T; Bagkeris E; Suri R
    J Cyst Fibros; 2015 Mar; 14(2):248-54. PubMed ID: 25127922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis.
    Elson EC; Meier E; Oermann CM
    J Cyst Fibros; 2021 Mar; 20(2):284-287. PubMed ID: 32811788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside ototoxicity in cystic fibrosis. Evaluation by high-frequency audiometry.
    McRorie TI; Bosso J; Randolph L
    Am J Dis Child; 1989 Nov; 143(11):1328-32. PubMed ID: 2816859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin.
    Garinis A; Gleser M; Johns A; Larsen E; Vachhani J
    J Cyst Fibros; 2021 Mar; 20(2):278-283. PubMed ID: 32713806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Assessment of the risk of hearing loss in children with cystic fibrosis].
    Polyakov DP; Daikhes NA; Bazanova MV; Melyanovskaya YL
    Vestn Otorinolaringol; 2024; 89(3):29-35. PubMed ID: 39104270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycoside ototoxicity.
    Zheng Y; Schachern PA; Sone M; Papapella MM
    Otol Neurotol; 2001 Mar; 22(2):266-8. PubMed ID: 11300281
    [No Abstract]   [Full Text] [Related]  

  • 10. Sensorineural hearing loss in patients with cystic fibrosis.
    Cheng AG; Johnston PR; Luz J; Uluer A; Fligor B; Licameli GR; Kenna MA; Jones DT
    Otolaryngol Head Neck Surg; 2009 Jul; 141(1):86-90. PubMed ID: 19559964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-interval aminoglycoside administration for children: a meta-analysis.
    Contopoulos-Ioannidis DG; Giotis ND; Baliatsa DV; Ioannidis JP
    Pediatrics; 2004 Jul; 114(1):e111-8. PubMed ID: 15231982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation: Ototoxicity following tobramycin treatment.
    Harruff EE; Kil J; Ortiz MGT; Dorgan D; Jain R; Poth EA; Fifer RC; Kim YJM; Shoup AG; Flume PA
    J Cyst Fibros; 2021 Mar; 20(2):288-294. PubMed ID: 33341407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity of aminoglycoside antibiotics in infants and children.
    Assael BM; Parini R; Rusconi F
    Pediatr Infect Dis; 1982; 1(5):357-65. PubMed ID: 6760147
    [No Abstract]   [Full Text] [Related]  

  • 14. High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients.
    Geyer LB; Menna Barreto SS; Weigert LL; Teixeira AR
    Braz J Otorhinolaryngol; 2015; 81(6):589-97. PubMed ID: 26480907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.
    Al-Malky G; Suri R; Dawson SJ; Sirimanna T; Kemp D
    Int J Audiol; 2011 Feb; 50(2):112-22. PubMed ID: 21265638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.
    Crifo S; Antonelli M; Gagliardi M; Lucarelli N; Marcolini P
    Int J Pediatr Otorhinolaryngol; 1980 Sep; 2(3):251-3. PubMed ID: 6821312
    [No Abstract]   [Full Text] [Related]  

  • 17. Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients.
    Gleser MA; Zettner EM
    Int J Audiol; 2018 Dec; 57(12):917-924. PubMed ID: 30382794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hearing loss in cystic fibrosis.
    Martins LM; Camargos PA; Becker HM; Becker CG; Guimarães RE
    Int J Pediatr Otorhinolaryngol; 2010 May; 74(5):469-73. PubMed ID: 20189661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Medicamentous test for the screening of pharmacogenic risk of aminoglycoside ototoxicity].
    Abakarov MG; Magomedov MM; Belousov IuB; Gotovskiĭ MIu
    Vestn Otorinolaringol; 2008; (6):48-51. PubMed ID: 19156118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort.
    Blankenship CM; Hunter LL; Feeney MP; Cox M; Bittinger L; Garinis AC; Lin L; McPhail G; Clancy JP
    Am J Audiol; 2021 Oct; 30(3S):834-853. PubMed ID: 33465313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.